2025
Association of Endocrinologists in Clinical Care Team With Sodium–Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study
Yi Y, Kumar N, Smith M, Mueller A, Houle T, Jassar A, Cornella L, Schonberger R, Bardia A. Association of Endocrinologists in Clinical Care Team With Sodium–Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study. Clinical Diabetes 2025 DOI: 10.2337/cd24-0107.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Coronary Artery Bypass GraftingType 2 diabetesArtery Bypass GraftingInhibitor prescriptionBypass GraftingSodium-glucose cotransporter 2 inhibitorsTwo-center studyCotransporter 2Sodium-glucosePostoperative careEndocrinologistsClinical care teamTwo-centerPatientsTreatment teamPrescription
2024
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.
McCoy R, Swarna K, Neumiller J, Polley E, Deng Y, Mickelson M, Herrin J. Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clinical Diabetes 2024, 43: 59-70. PMID: 39829688, PMCID: PMC11739335, DOI: 10.2337/cd24-0007.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Moderate cardiovascular disease riskRisk of severe hypoglycemiaGlucose-lowering therapyCardiovascular disease riskType 2 diabetesSevere hypoglycemiaSodium-glucose cotransporter 2 inhibitorsDPP-4GLP-1 receptor agonistsGlucagon-like peptide 1Risk of hypoglycemiaDPP-4 inhibitorsDipeptidyl peptidase 4Disease riskAvoidance of hypoglycemiaSulfonylurea therapyReceptor agonistsCotransporter 2Sulfonylurea usePatient populationGLP-1Peptidase 4HypoglycemiaEmergency departmentEffects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure Results From SOLOIST-WHF
Bhatt A, Bhatt D, Steg P, Szarek M, Cannon C, Leiter L, McGuire D, Lewis J, Riddle M, Voors A, Metra M, Lund L, Testani J, Wilcox C, Davies M, Pitt B, Kosiborod M. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure Results From SOLOIST-WHF. Journal Of The American College Of Cardiology 2024, 84: 1078-1088. PMID: 39260929, DOI: 10.1016/j.jacc.2024.06.036.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Effect of sotagliflozinKCCQ-12 scoreKCCQ-12Heart failureSOLOIST-WHFPrimary endpointSodium-glucose cotransporter 2 inhibitionLeft ventricular ejection fractionWorsening Heart FailureBaseline to monthVentricular ejection fractionHealth statusWorsening HFKansas City Cardiomyopathy Questionnaire-12Ejection fractionSecondary endpointsCotransporter 2Randomized patientsClinical characteristicsHF hospitalizationPlaceboCardiovascular deathHF episodeSotagliflozinPrescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin J, Xu Y, Chang A, Carrero J, Flaherty C, Mukhopadhyay A, Inker L, Blecker S, Horwitz L, Grams M. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. Journal Of The American College Of Cardiology 2024, 84: 683-693. PMID: 39142721, PMCID: PMC11789666, DOI: 10.1016/j.jacc.2024.05.057.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Class 1A recommendationSodium-glucose cotransporter 2 inhibitor therapyChronic kidney diseaseU.S. health systemHealth systemInhibitor prescriptionHeart failurePrescription ratesInhibitor therapyInhibitor useSodium-glucose cotransporter 2 inhibitorsSodium-glucose cotransporter 2 inhibitor useOptum Labs Data WarehouseProportion of patientsSGLT2 inhibitor usePresence of diabetesRecurrent cardiovascular eventsAtherosclerotic cardiovascular diseaseCotransporter 2Analysis of U.S. dataSevere albuminuriaPrescription patternsCardiovascular eventsCommercial insurance
2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Moura F, Berg D, Bellavia A, Dwyer J, Mosenzon O, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Braunwald E, Morrow D, Sabatine M. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care 2023, 46: 1807-1815. PMID: 37556796, PMCID: PMC10516252, DOI: 10.2337/dc23-0492.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Kidney disease progressionPredictors of kidney disease progressionAbsolute risk reductionDisease progressionValidation cohortType 2 diabetesSodium-glucose cotransporter 2 inhibitionUrine albumin-to-creatinine ratioAlbumin-to-creatinine ratioEfficacy of dapagliflozinMedian Follow-UpRisk categoriesMultivariate Cox regressionRelative risk reductionHigh-risk groupAtherosclerotic cardiovascular diseaseSystolic blood pressureRisk reductionMagnitude of benefitDapagliflozin EffectT2D durationCotransporter 2SGLT2 inhibitionStratify risk
2020
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. Journal Of Biological Chemistry 2020, 295: 14379-14390. PMID: 32796035, PMCID: PMC7573269, DOI: 10.1074/jbc.rev120.008387.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSodium-glucose cotransporter 2SGLT2 inhibitorsEuglycemic ketoacidosisGlucose reabsorptionTherapeutic promiseSGLT2 inhibitor therapyLower plasma glucose concentrationsModest weight lossGlucose-lowering agentsRenal glucose reabsorptionType 2 diabetesType 1 diabetesPlasma glucose concentrationGlucose concentrationBlood glucose concentrationHeart failureInhibitor therapyAtrial fibrillationCardiovascular diseaseCotransporter 2Preclinical studiesHealthy personsClinical utilityDiabetes managementProximal tubules
2013
Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the Kcc2 promoter
Yeo M, Berglund K, Hanna M, Guo J, Kittur J, Torres M, Abramowitz J, Busciglio J, Gao Y, Birnbaumer L, Liedtke W. Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the Kcc2 promoter. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 4315-4320. PMID: 23440186, PMCID: PMC3600491, DOI: 10.1073/pnas.1300959110.Peer-Reviewed Original ResearchMeSH KeywordsAir Pollutants, OccupationalAnimalsBenzhydryl CompoundsCells, CulturedCentral Nervous System DiseasesCerebral CortexChloridesDNA-Binding ProteinsEpigenesis, GeneticFemaleHistone Deacetylase 1HumansK Cl- CotransportersMaleMiceNerve Tissue ProteinsNeuronsPhenolsRatsResponse ElementsSex CharacteristicsSymportersConceptsEffects of bisphenol AKcc2 promoterBisphenol A exposureKCC2 expressionCortical neuronsHistone deacetylase 1Binding of methyl-CpG-binding protein 2Potassium-chloride cotransporter 2KCC2 gene expressionMethyl-CpG-binding protein 2Knockdown of histone deacetylase 1Sexually dimorphic mannerSexually dimorphic effectsHuman neurodevelopmental disordersBisphenol-A effectsHuman cortical neuronsToxic mechanisms of bisphenol ANeuronal chlorideCotransporter 2Cortical slicesBinding protein 2KCC2Mouse damsDimorphic mannerInterneuron migration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply